- Home
- LKFN vs ARVN Comparison
LKFN vs ARVN Comparison
Compare LKFN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LKFN
- ARVN
- Stock Information
- Founded
- LKFN 1872
- ARVN 2015
- Country
- LKFN United States
- ARVN United States
- Employees
- LKFN N/A
- ARVN N/A
- Industry
- LKFN Major Banks
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- LKFN Finance
- ARVN Health Care
- Exchange
- LKFN Nasdaq
- ARVN Nasdaq
- Market Cap
- LKFN 1.7B
- ARVN 1.7B
- IPO Year
- LKFN 1997
- ARVN 2018
- Fundamental
- Price
- LKFN $73.61
- ARVN $25.11
- Analyst Decision
- LKFN Hold
- ARVN Strong Buy
- Analyst Count
- LKFN 3
- ARVN 13
- Target Price
- LKFN $71.00
- ARVN $61.08
- AVG Volume (30 Days)
- LKFN 127.7K
- ARVN 718.1K
- Earning Date
- LKFN 10-25-2024
- ARVN 10-30-2024
- Dividend Yield
- LKFN 2.66%
- ARVN N/A
- EPS Growth
- LKFN 9.99
- ARVN N/A
- EPS
- LKFN 3.85
- ARVN N/A
- Revenue
- LKFN $242,401,000.00
- ARVN $161,100,000.00
- Revenue This Year
- LKFN N/A
- ARVN $237.44
- Revenue Next Year
- LKFN $1.35
- ARVN N/A
- P/E Ratio
- LKFN $19.12
- ARVN N/A
- Revenue Growth
- LKFN 3.62
- ARVN 1.07
- 52 Week Low
- LKFN $53.97
- ARVN $21.17
- 52 Week High
- LKFN $78.31
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- LKFN 60.77
- ARVN 48.81
- Support Level
- LKFN $71.63
- ARVN $21.17
- Resistance Level
- LKFN $77.20
- ARVN $28.70
- Average True Range (ATR)
- LKFN 2.57
- ARVN 1.72
- MACD
- LKFN 0.05
- ARVN -0.41
- Stochastic Oscillator
- LKFN 68.31
- ARVN 51.44
About LKFN Lakeland Financial Corporation
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. Lakeland offers a broad range of products and services throughout its Northern and Central Indiana markets. The company offers commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.